Ann: Topical CBD pain study with Lambert Initiative approved, page-3

Preclinical evidence for localised use of CBD in arthritis

Conclusions

This study showed for the first time that local CBD administration inhibited pain and peripheral sensitisation in established OA. Topical treatment with CBD reduced leukocyte trafficking and joint hyperaemia during the early stages of MIA. By attenuating this initial inflammatory response with CBD, end-stage OA pain and peripheral neuropathy were abrogated. Thus, CBD may be a safe therapeutic to treat OA pain locally as well as block the acute inflammatory flares that drive disease progression and joint neuropathy.

Philpott HT, O'Brien M, McDougall JJ. "Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis". Pain. 2017;158(12):2442-2451. doi:10.1097/j.pain.0000000000001052

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690292/